Anavex Life Sciences AVXL

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.11 (+1.28%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Anavex Life Sciences (AVXL)
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $8.67

  • Market Cap

    $737.51 Million

  • Price-Earnings Ratio

    -61.93

  • Total Outstanding Shares

    85.06 Million Shares

  • Total Employees

    2

  • Dividend

    No dividend

  • IPO Date

    August 2, 2006

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    630 5th avenue, New york, NY, 10111

  • Homepage

    https://www.anavex.com

Historical Stock Splits

If you bought 4 shares of AVXL before October 7, 2015, you'd have 1 share today.
Execution DateSplit Amount
October 7, 20151-for-4 (Reverse Split)

Cash Flow Statement

October 1, 2024 to December 31, 2024
MetricValue
Net Cash Flow From Investing Activities$11.41 Million
Net Cash Flow From Investing Activities, Continuing$11.41 Million
Net Cash Flow From Operating Activities$-12.12 Million
Net Cash Flow, Continuing$0
Net Cash Flow From Financing Activities, Continuing$708,000
Net Cash Flow From Operating Activities, Continuing$-12.12 Million

Income Statement

October 1, 2024 to December 31, 2024
MetricValue
Diluted Average Shares$84.81 Million
Operating Income/Loss$-13.59 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
Basic Earnings Per Share$-0.14
Revenues$1.39 Million
Other Operating Expenses$3.15 Million

Comprehensive Income

October 1, 2024 to December 31, 2024
MetricValue
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss Attributable To Parent$-12.11 Million
Comprehensive Income/Loss$-12.11 Million
Other Comprehensive Income/Loss$0

Balance Sheet

October 1, 2024 to December 31, 2024
MetricValue
Current Liabilities$13.13 Million
Accounts Payable$4.57 Million
Equity Attributable To Parent$110.92 Million
Liabilities And Equity$124.04 Million
Noncurrent Liabilities$0
Other Current Liabilities$8.56 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about AVXL from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.